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BACKGROUND TAVI is now the treatment of choice for patients pre-
senting with severe symptomatic aortic stenosis who are deemed to
be inoperable or of high surgical risk. During the last few years, rapid
improvements have been made to TAVI devices coupled with greater
operator and institutional experience. We sought to determine the
patient and healthcare beneﬁts of contemporary TAVI practice.
METHODS A retrospective analysis was conducted of all patients that
underwent transfemoral TAVI between November 2007 and May 2015
at San Raffaele Scientiﬁc Institute, Milan, Italy. The ﬁrst 150 patients
treated were allocated to the early experience group (EE), and the last
150 patients to the contemporary practice group (CP).
RESULTS Patients were older in the EE group (85.1 vs. 81.5 years,
p<0.001) and of higher risk (10.8 vs. 9.7, p¼0.003) when compared to
the CP group. In the EE group, general anesthetic (22.7% vs. 5.3%,
p<0.001) and surgical cut-down (4% vs. 0%, p<0.001) were more
frequent in comparison to the CP group. Procedure times were also
longer in the EE group (110.4 vs. 74.6 minutes, p¼0.004) as was the
volume of contrast used (208.8 vs. 76.9 milliliters, p<0.001). This
translated into a signiﬁcant reduction in hemoglobin drop (2.4 vs. 1.7
grams/deciliter, p¼0.02) but without a signiﬁcant impact upon plasma
creatinine rise (0.23 vs. 0.18, p¼0.6). As a consequence of these im-
provements patient length of stay was signiﬁcantly shorter in the CP
group (7.2 vs. 9.4 days, p¼0.04).
CONCLUSIONS Advances in TAVI technology, coupled with greater
operator and institutional experience has resulted in signiﬁcant im-
provements in contemporary TAVI practice. In our single high-volume
center experience, this has translated into shorter, less invasive pro-
cedures that have resulted in a signiﬁcantly shorter length of stay.
These improvements have resulted in advantages to both patients(e.g. reduced risk of nosocomial infection) and the healthcare system
with reduced economics costs coupled with beneﬁts of improved
patient ﬂow enabling greater number of patients to be treated.
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BACKGROUND Moderate or severe aortic insufﬁciency (AI) after
transcatheter aortic valve implantation (TAVI) with ﬁrst generation
devices increased acute and long-term mortality. Post-dilation in or-
der to improve procedural outcome increased acute stroke rate. Sec-
ond generation devices are designed to reduce the risk for relevant AI
and offer more control regarding valve positioning. We compared the
repositionable Lotus valve with the balloon-expandable Edwards Sa-
pien 3 valve regarding acute and 30 days outcomes (Clinical Trial
Registration: NCT02162069).
METHODS We evaluated post-procedural AI, need for post-dilation,
rate of permanent pacemaker implantation, and device success ac-
cording to VARC criteria in 221 patients with severe aortic stenosis
undergoing transfemoral TAVI. The repositionable Lotus valve (N¼71)
or the balloon-expandable Edwards Sapien 3 (ES3) valve (N¼150) were
implanted. Baseline parameters did not differ between Lotus and ES3
group with: pulmonary disease 57% vs 57% (p¼0.99), NYHA III or IV in
79% vs 84% (p¼0.30), aortic valve area by echocardiography
0.820.49 cm2 vs 0.800.28 cm2, STS and Euro-Scores. For sizing a
256 multisclice computed tomography (MSCT, Philips Brilliance iCT)
with retrospective ECG triggering was done. Measurements were
performed in systole and area and perimeter derived diameters of the
annulus and left ventricular outﬂow tract were measured. Baseline
MSCT data did not differ with area derived annulus diameter of
24.71.7mm in the Lotus group and 24.72.6mm in the ES3 group
(p¼0.85). Perimeter derived diameter was 25.31.7mm vs
25.42.6mm (p¼0.75). Number of area and perimeter derived di-
ameters of the LVOT were 24.62.2mm vs 24.72.7mm (p¼0.73) and
25.42.3mm vs 25.72.9mm (p¼0.44), respectively. Measurements
were performed with a dedicated software (3mensio 7.0 software, Pie
Medical Imaging, Maastricht, The Netherlands).
RESULTS Post TAVI there was no moderate or severe AI, no need for
post-dilation or use of a second valve in both groups. Contrast amount
was 10738ml for Lotus and 8725ml for ES3 implantation (p<0.05).
There was no moderate or severe AI by echocardiography one day
after TAVI in both groups. There were no death, stroke, annulus
rupture or coronary obstruction. Device success did not differ be-
tween groups and need for pacemaker implantation was signiﬁcantly
higher with Lotus compared with ES3, respectively. Mean regurgita-
tion index was 29.19.2 vs 25.29.7 for Lotus vs ES3 (p¼0.01), mean
aortic gradient by echocardiography 12.04.1mmHg vs
12.64.9mmHg (p¼0.39), respectively.
CONCLUSIONS TAVI with the repositionable Lotus Valve System and
the balloon-expandable Edwards Sapien 3 demonstrated similar acute
and 30 days results. With both second generation TAVI devices there
was no moderate or severe aortic insufﬁciency and no need for post-
dilatation. Device success was similar between groups while need for
permanent pacemaker was signiﬁcantly higher with the Lotus Valve.
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BACKGROUND Recently, a novel balloon-expandable transcatheter
heart valve (THV), the SAPIEN 3 (S 3) has been introduced. While
preliminary data on clinical performance with this device is
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evaluated outcomes after TAVI with S3 THV with particular emphasis
on the updated Valve Academic Research Consortium (VARC-2)
criteria.
METHODS 261 consecutive patients undergoing transfemoral TAVI
with S3 THV at our center were enrolled and outcome according to the
VARC-2 criteria was analyzed at 30 days.
RESULTS Mean age was 816 years and median logistic EuroScore
was 12% [8-21]. Follow-up at 30 days was available for 260 pa-
tients. VARC-2 deﬁned device success was achieved in 251 (96%) of
patients; 5 (2%) cases developed moderate paravalvular leakage. At
30 days, one patient (0.4%) died due to a noncardiac cause and 8
(3%) patients suffered from a disabling (n¼4) or non-disabling
stroke (n¼4). Life-threatening bleeding and major vascular com-
plications occurred in 12 (5%) and 7 (3%) of the cases, respectively.
From discharge to 30 days, 5 (2%) patients were hospitalized due
to valve-related symptoms or worsening of heart failure. The
VARC-2 composite early safety endpoint at 30 days, all-cause
mortality, disabling and non-disabling stroke, life-threatening
bleeding, acute kidney injury, coronary artery obstruction requiring
intervention, major vascular complication, or valve-related
dysfunction requiring repeat procedure was observed in 23 (9%)
patients. Permanent pacemaker implantation rate at 30 days was
16% (38 of the 235 patients without pacemaker at baseline) and
with 30-days follow-up. Myocardial infarction, coronary obstruction
requiring intervention, valve-related dysfunction and endocarditis
were not observed.
Clinical outcome in-hospital and at 30 daysIn-hospital events
(n [ 261)At 30 Days*
(n [ 260)All-cause mortality 0 (0) 1 (0.4)Disabling stroke 3 (1) 4 (1.5)Non-disabling stroke 4 (2) 4 (1.5)Hospitalization for valve-
related symptoms or
worsened CHF- 5 (2)Major vascular complication 8 (3) 7 (3)Life-threatening bleeding 11 (4) 12 (5)AKI 2/3, including renal
replacement therapy5 (2) 4 (2)Coronary artery obstruction
requiring intervention0 (0) 0 (0)Myocardial infarction 0 (0) 0 (0)Valve-related dysfunction
requiring repeat procedure
(BAV, TAVI or SAVR)0 (0) 0 (0)Endocarditis (n, %) 0 (0) 0 (0)Valve thrombosis 0 (0) 0 (0)New pacemaker** 35 (15) 38 (16)VARC-2 early safety composite
endpoint at 30 Days- 23 (9)All data are absolute number (percentage)
Abbreviations: CHF ¼ Congestive heart failure; AKI ¼ Acute kidney injury; VARC ¼ Valve Academic Research
Consortium; *1 patient lost to follow-up, **excluding patients with prior pacemaker (n¼235)
CONCLUSIONS We found very good 30-day results using a novel
balloon expandable S3 THV with a low rate of severe clinical events
according to the VARC-2 composite early safety endpoint. The novel
balloon expandable S3 THV is associated with a high procedural suc-
cess rate and favorable early safety proﬁle considering the VARC-2
composite endpoint. The need for pacemaker implantations appears
to be more frequent than that seen with its predecessor.
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ability of transcatheter heart valve replacement (TAVR) therapy on
overall heart valve replacement volumes and aortic valve disease
mortality over a longer-term horizon, using the German healthcare
system as a reference case, which was among the ﬁrst systems
adopting TAVR therapy in routine care.
METHODS We collected therapy- and age-speciﬁc procedure vol-
umes from records of the German Federal Statistics Ofﬁce for TAVR
and surgical aortic valve replacement (SAVR) procedures for years
2009-2013. Relevant ICD-10 diagnosis-based information about dis-
charges and hospital-based mortality were obtained for the same
period. We computed therapy-speciﬁc and total procedure volumes
and growth stratiﬁed by 5-year age increments and in total.
Discharge and mortality data for aortic valve disease hospitaliza-
tions was assessed to obtain an estimate of changes in per-case
mortality.
RESULTS Overall procedure volumes grew from 26,466 in 2009 to
33,235 in 2013 (þ26%). This growth was driven by TAVR (3,411 to
10,814; þ217%), while SAVR volumes remained stable (23,055 to
22,421; -3%). In patients 75 years or older, an overall procedure
growth of 51% was observed (12,168 to 18,318), with volumes in
older patient segments growing more heavily (þ62% in >80-year
olds; þ101% in >85-year olds). Across all elderly age groups, SAVR
volumes decreased (-20% in >80 year olds; -37% in >85 year olds),
while they grew in selected younger patients groups (highest
growth þ30% in age group 60-64 yrs.). Concurrently, total aortic
valve disease hospital discharges grew by 26%, from 44,161 to
55,748, while mortality per hospitalization case decreased by 5%
between 2009 and 2013.
CONCLUSIONS Five-year real world data from the German healthcare
system demonstrate that the availability of TAVR has led to substantial
growth in aortic valve replacements. TAVR substantially increased
volumes in the elderly population, and partially replaced SAVR treat-
ments in this subgroup. Concurrently, increased therapy utilization in
patients previously left untreated was associated with a reduction in
overall mortality of aortic valve-related hospitalizations. Further
analysis is warranted to compare these data with the German Registry
as well as replicate them in other countries, if possible stratiﬁed by
pre-procedure surgical risk.
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BACKGROUND To overcome limitations of transapical and trans-
septal access to deliver large caliber transcatheter implants to the
mitral valve, we hypothesized that the left atrium could be accessed
through the posterior chest wall by displacing the lung with CO2 un-
der imaging guidance.
METHODS We tested fully percutaneous transthoracic left atrial ac-
cess in 12 animals (10 pigs and 2 sheep) and 3 human cadavers under
real-time magnetic resonance imaging (n¼10) or x-ray ﬂuoroscopy
plus C-arm computed tomographic (n¼2) guidance. We also simulated
transthoracic trajectories to the left atrium on human contrast-
enhanced cardiac computed tomographic angiograms.
RESULTS Animals were survived for median 7.5 days (Q1-Q3, 7–8.5
days). The pleural space was insufﬂated with CO2 to displace the
lung, an 18-26F sheath was delivered to the left atrium, and the left
atrial port was closed using an off-the-shelf nitinol cardiac occluder
(Amplatz Atrial Septal Occluder) successfully in 12/12 animals.
There was no procedural mortality and no important change in
hemodynamics (heart rate, mean arterial pressure and expired
CO2). Median bleeding into the pericardium and pleura were 55mL
(40–73mL) and 10mL (10–75mL) respectively, which were immedi-
ately auto-transfused.1 hemodynamically insigniﬁcant pericardial
effusion was observed at follow-up. We also successfully accessed
and closed the left atrium in 3 human cadavers under real-time
magnetic resonance (n¼1) or X-ray ﬂuoroscopic guidance (n¼2). A
theoretical trajectory to the left atrium, assuming the right lung
